Cutting Edge: Programmed Death-1/Programmed Death Ligand 1 Interaction Regulates the Induction and Maintenance of Invariant NKT Cell Anergy

被引:120
|
作者
Chang, Woo-Sung [1 ,2 ]
Kim, Ji-Yeon [1 ,2 ]
Kim, Yeon-Jeong [1 ,2 ]
Kim, Yun-Sun [1 ,2 ]
Lee, Jung-Mi [1 ,2 ]
Azuma, Miyuki [3 ]
Yagita, Hideo [4 ]
Kang, Chang-Yuil [1 ,2 ]
机构
[1] Seoul Natl Univ, Coll Pharm, Immunol Lab, Seoul 151742, South Korea
[2] Seoul Natl Univ, Coll Pharm, Pharmaceut Sci Res Inst, Seoul 151742, South Korea
[3] Tokyo Med & Dent Univ, Dept Mol Immunol, Tokyo, Japan
[4] Juntendo Univ, Sch Med, Dept Immunol, Tokyo 113, Japan
来源
JOURNAL OF IMMUNOLOGY | 2008年 / 181卷 / 10期
关键词
D O I
10.4049/jimmunol.181.10.6707
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Invariant NKT (iNKT) cells are a distinct subset of T lymphocytes that recognize glycolipid Ags. Upon TCR stimulation, iNKT cells promptly secrete a wide range of cytokines and therefore have been investigated as a target for immunotherapy. However, after primary activation, iNKT cells become hyporesponsive toward their ligand (anergy). The further mechanism behind iNKT cell anergy is poorly understood. We found that a low level of programmed death-1 (PD-1) was constitutively expressed on iNKT cells and that PD-1 expression was increased after stimulation and lasted at least 2 mo. Moreover, not only did blocking of the PD-1/PD ligand 1 (PD-L1) pathway prevent the induction of anergy in iNKT cells, but anergic NKT cells also recovered responsiveness and these "rescued" cells efficiently mediated antitumor immunity. Our findings suggest that the PD-1/PD-L1 interaction is essential for the induction and maintenance of iNKT cell anergy. The Journal of Immunology, 2008,181: 6707-6710.
引用
收藏
页码:6707 / 6710
页数:4
相关论文
共 50 条
  • [21] Clinical Significance of Programmed Death-1 Ligand-2 in Esophageal Cancer: Comparison with Programmed Death-1 Ligand-1
    Okadome, Kazuo
    Baba, Yoshifumi
    Yagi, Taisuke
    Kiyozumi, Yuki
    Eto, Kojiro
    Hiyoshi, Yukiharu
    Ishimoto, Takatsugu
    Nagai, Yohei
    Iwagami, Shiro
    Miyamoto, Yuji
    Yoshida, Naoya
    Baba, Hideo
    CANCER SCIENCE, 2018, 109 : 414 - 414
  • [22] Discovery of phenyl-linked symmetric small molecules as inhibitors of the programmed cell death-1/programmed cell death-ligand 1 interaction
    Wu, Yizhe
    Zhang, Yu
    Guo, Yu
    Pan, Zhichao
    Zhong, Shichun
    Jin, Xinxin
    Zhuang, Weihao
    Chen, Sikang
    Gao, Jian
    Huang, Wenhai
    Dong, Xiaowu
    Che, Jinxin
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 223
  • [23] Progress in programmed cell death-1/programmed cell death-ligand 1 pathway inhibitors and binding mode analysis
    Li, Xiaoyun
    Zeng, Qin
    Xu, Fengjiao
    Jiang, Yuying
    Jiang, Zhongmei
    MOLECULAR DIVERSITY, 2023, 27 (04) : 1935 - 1955
  • [24] Progress in programmed cell death-1/programmed cell death-ligand 1 pathway inhibitors and binding mode analysis
    Xiaoyun Li
    Qin Zeng
    Fengjiao Xu
    Yuying Jiang
    Zhongmei Jiang
    Molecular Diversity, 2023, 27 : 1935 - 1955
  • [25] OCULAR ADVERSE EVENTS ASSOCIATED WITH PROGRAMMED DEATH-1 AND PROGRAMMED DEATH LIGAND-1 IMMUNOTHERAPY
    Young, LeAnne
    Finnigan, Shanda
    Streicher, Howard
    Chen, Helen
    Murray, James
    Sen, H. Nida
    Sharon, Elad
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A386 - A387
  • [26] Programmed cell death-1 regulates neuronal cell death in the developing mouse retina
    Sham, Caroline
    Chen, Ling
    Wu, Yin
    Sharpe, Arlene
    Freeman, Gordon
    Braun, Jonathan
    Gordon, Lynn
    CLINICAL IMMUNOLOGY, 2008, 127 : S141 - S142
  • [27] Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy
    Naidoo, Jarushka
    Wang, Xuan
    Woo, Kaitlin M.
    Iyriboz, Tunc
    Halpenny, Darragh
    Cunningham, Jane
    Chaft, Jamie E.
    Segal, Neil H.
    Callahan, Margaret K.
    Lesokhin, Alexander M.
    Rosenberg, Jonathan
    Voss, Martin H.
    Rudin, Charles M.
    Rizvi, Hira
    Hou, Xue
    Rodriguez, Katherine
    Albano, Melanie
    Gordon, Ruth-Ann
    Leduc, Charles
    Rekhtman, Natasha
    Harris, Bianca
    Menzies, Alexander M.
    Guminski, Alexander D.
    Carlino, Matteo S.
    Kong, Benjamin Y.
    Wolchok, Jedd D.
    Postow, Michael A.
    Long, Georgina V.
    Hellmann, Matthew D.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07) : 709 - +
  • [28] Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer
    Liu, Xiaojun
    Yang, Zhongxia
    Latchoumanin, Olivier
    Qiao, Liang
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2016, 9 (06): : 853 - 860
  • [29] Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer
    Ohigashi, Y
    Sho, M
    Yamada, Y
    Tsurui, Y
    Hamada, K
    Ikeda, N
    Mizuno, T
    Yoriki, R
    Kashizuka, H
    Yane, K
    Tsushima, F
    Otsuki, N
    Yagita, H
    Azuma, M
    Nakajima, Y
    CLINICAL CANCER RESEARCH, 2005, 11 (08) : 2947 - 2953
  • [30] Rare Adverse Events with Programmed Death-1 and Programmed Death-1 Ligand Inhibitors: Justification and Rationale for a Systematic Review
    Smith, Caleb J.
    Almodallal, Yahya
    Jatoi, Aminah
    CURRENT ONCOLOGY REPORTS, 2021, 23 (07)